-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

602.O4.6 602. Myeloid Oncogenesis: Basic: Therapeutic Targeting of Myeloid Malignancies

Symposia: Myeloid Oncogenesis: Basic Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Fundamental Science, Lymphoid Leukemias, ALL, Antibody Therapy, Biological therapies, Acute Myeloid Malignancies, AML, Lymphomas, non-Hodgkin lymphoma, Translational Research, CHIP, genomics, Plasma Cell Disorders, Clinical Research, hematopoiesis, Diseases, immune mechanism, indolent lymphoma, Therapies, immunology, aggressive lymphoma, Lymphoid Malignancies, Myeloid Malignancies, Biological Processes, Technology and Procedures, molecular biology, Minimal Residual Disease , molecular testing
Saturday, December 10, 2022: 9:30 AM-11:00 AM
353-355 (Ernest N. Morial Convention Center)
Andre Catic, MD, PhD, Baylor College of Medicine and Ann Mullally, MD, Brigham and Women's Hospital
No relevant conflicts of interest to declare.
Fundamental Research Relating to New Therapeutic Opportunities to Target AML and CML.
9:30 AM

Dorien Pastoors, MSc1,2*, Marije Havermans1,2*, Remco Hoogenboezem, MSc3*, Roger Mulet-Lazaro, MSc1,2*, Duncan Brian, BSc4*, Leonie Smeenk, PhD1,2*, Claudia Erpelinck-Verschueren1,2*, Stanley van Herk, BSc1,2*, Bas Wouters, MD/PhD1,2*, Jeroen A.A. Demmers, PhD5*, Johannes Zuber, MD6*, Tariq Enver, PhD7*, Richard WJ Groen8,9*, Eric Bindels, PhD1* and Ruud Delwel, MD1,2

1Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
2Oncode Institute, Rotterdam, Netherlands
3Department of Hematology, Erasmus MC Cancer Institute, Rotterdam, Netherlands
4Stem Cell Group, UCL Cancer Institute, University College London, London, United Kingdom
5Proteomics Center, Erasmus MC, Rotterdam, Netherlands
6Research Institute of Molecular Pathology (IMP), Vienna, Austria
7University College London Cancer Institute, London, United Kingdom
8Hematology, Amsterdam UMC, location VU University Medical Center, Amsterdam, Netherlands
9Cancer Center Amsterdam, Amsterdam, Netherlands

9:45 AM

Yosuke Masamoto, MD, PhD1, Akira Chiba, MD, PhD1, Toshiya Hino, MD, PhD2*, Hiroki Hayashida, MD2*, Hideaki Mizuno, MD1*, Tomohiko Sato, MD, PhD1,3 and Mineo Kurokawa4*

1Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
2The University of Tokyo Hospital, Tokyo, TKY, JPN
3Division of Transfusion Medicine and Cell Therapy, The Jikei University Hospital, Tokyo, Japan
4Graduate School of Medicine, The University of Tokyo, Bunkyo-Ku, Tokyo, JPN

10:00 AM

TaeKon Kim, MD1, Xue Han, PhD2*, Qianni Hu, PhD3*, Carly Hedgepath4*, Junshik Hong, MD4,5, Jihyun Park3,6*, Emily F Mason, MD, PhD7* and Lieping Chen, MD, Ph.D.8*

1Division of hematology/oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
2Department of Microbial Infection and Immunity, College of Medicine, The Ohio State University, Pelotonia Institute for Immuno-Oncology, OSUCCC – James, The Ohio State University, Columbus, OH
3Vanderbilt University Medical Center, Nashville, TN
4Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN
5Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic of (South)
6Center for Medical Innovation, Seoul National University Hospital, Seoul, Korea, Republic of (South)
7Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville
8Department of Immunobiology, Yale School of Medicine, New Haven, CT

10:15 AM

Yinghui Zhu, PhD1,2*, Miso Park, PhD3*, Mariam Murtadha, PhD1,2*, Enrico Caserta, PhD1,2*, Le Xuan Truong Nguyen, PhD4*, Mahmoud Singer, PhD1,2*, Marc Denisse Estepa1,2*, Lokesh Nigam, PhD1,2*, Ada Alice Dona', PhD1,2*, James F Sanchez, PhD1*, Theophilus Tandoh, PhD1,2*, Man Li, PhD2*, Bin Zhang, PhD2*, Ya-Huei Kuo, PhD2, Guido Marcucci, MD2, John C Williams, PhD3* and Flavia Pichiorri, PhD1,2

1Judy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, CA
2Department of Hematologic Malignancies Translational Science, Beckman Research Institute, City of Hope, Duarte, CA
3Department of Molecular Medicine, Beckman Research Institute, City of Hope, Duarte, CA
4Department of Hematological Malignancies Translational Science, Gehr Family Center for Leukemia Research, Hematology Malignancies and Stem Cell Transplantation Institute, Beckman Research Institute, City of Hope, Duarte, CA

10:30 AM

Yuichiro Semba, MD, PhD1*, Takuji Yamauchi, MD, PhD1*, Fumihiko Nakao, MD1*, Jumpei Nogami, PhD1*, Seishi Ogawa, MD, PhD2, Koichi Akashi, MD, PhD1 and Takahiro Maeda, MD, PhD3

1Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan
2Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto City, Japan
3Division of Precision Medicine, Kyushu University Graduate School of Medical Sciences, Fukuoka, Japan

10:45 AM

Mariko Morii, PhD1*, Sho Kubota, PhD1*, Mihoko Iimori1*, Ai Hamashima1*, Kimi Araki, PhD2,3* and Goro Sashida, MD, PhD1

1Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences, Kumamoto University, Kumamoto, Japan
2Institute of Resource Development and Analysis, Kumamoto University, Kumamoto, Japan
3Center for Metabolic Regulation of Healthy Aging, Kumamoto University, Kumamoto, Japan

*signifies non-member of ASH